Electromed (NYSE:ELMD) Downgraded by StockNews.com to Buy

StockNews.com cut shares of Electromed (NYSE:ELMD) from a strong-buy rating to a buy rating in a research report report published on Thursday morning.

Separately, TheStreet upgraded shares of Electromed from a c+ rating to a b- rating in a report on Wednesday, February 21st.

Electromed Trading Up 4.0 %

ELMD opened at $14.50 on Thursday. The firm has a market capitalization of $124.85 million, a PE ratio of 32.22 and a beta of 0.43. Electromed has a twelve month low of $8.80 and a twelve month high of $17.85. The firm’s 50-day moving average price is $15.34 and its 200 day moving average price is $12.14.

Electromed (NYSE:ELMD) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $0.19 earnings per share for the quarter. The firm had revenue of $13.69 million for the quarter. Electromed had a net margin of 7.62% and a return on equity of 10.32%.

Hedge Funds Weigh In On Electromed

Several large investors have recently made changes to their positions in ELMD. Gamco Investors INC. ET AL acquired a new position in shares of Electromed in the 4th quarter worth approximately $916,000. Royal Bank of Canada lifted its holdings in shares of Electromed by 15.7% in the 2nd quarter. Royal Bank of Canada now owns 150,125 shares of the company’s stock worth $1,608,000 after acquiring an additional 20,358 shares during the last quarter. Riverwater Partners LLC increased its stake in Electromed by 83.5% during the 3rd quarter. Riverwater Partners LLC now owns 32,684 shares of the company’s stock worth $340,000 after buying an additional 14,871 shares during the period. Cetera Advisor Networks LLC purchased a new stake in Electromed during the 2nd quarter worth approximately $129,000. Finally, Renaissance Technologies LLC increased its stake in Electromed by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 53,504 shares of the company’s stock worth $556,000 after buying an additional 10,700 shares during the period. 40.82% of the stock is currently owned by institutional investors and hedge funds.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function.